DNA Repair Drugs Market (Drug Type: PARP Inhibitors, Alkylating Agents, and Others; and Dosage Form: Tablets, Capsules, and Injectable) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

DNA Repair Drugs Market (Drug Type: PARP Inhibitors, Alkylating Agents, and Others; and Dosage Form: Tablets, Capsules, and Injectable) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031


DNA Repair Drugs Market – Scope of Report


TMR’s report on the global DNA Repair Drugs Market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global DNA Repair Drugs Market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global DNA Repair Drugs Market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the DNA Repair Drugs Market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global DNA Repair Drugs Market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global DNA Repair Drugs Market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global DNA Repair Drugs Market.

The report delves into the competitive landscape of the global DNA Repair Drugs Market. Key players operating in the global DNA Repair Drugs Market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global DNA Repair Drugs Market profiled in this report.

Key Questions Answered in Global DNA Repair Drugs Market Report
  • What is the sales/revenue generated by mobile photo printer across all regions during the forecast period?
  • What are the opportunities in the global DNA Repair Drugs Market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?
DNA Repair Drugs Market – Research Objectives and Research Approach

The comprehensive report on the global DNA Repair Drugs Market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global DNA Repair Drugs Market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global DNA Repair Drugs.


1. Preface
  1.1. Market Definition and Scope
  1.2. Market Segmentation
  1.3. Key Research Objectives
  1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global DNA Repair Drugs Market
4. Market Overview
  4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
  4.2. Overview
  4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
  4.4. Global DNA Repair Drugs Market Analysis and Forecast, 2017-2031
5. Key Insights
  5.1. Technological Advancements
  5.2. Disease Prevalence & Incidence Rate Globally With Key Countries
  5.3. Pipeline Analysis
  5.4. Regulatory Scenario by Region/Globally
  5.5. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)
6. Global DNA Repair Drugs Market Analysis and Forecast, by Drug Type
  6.1. Introduction & Definition
  6.2. Key Findings/Developments
  6.3. Market Value Forecast, by Drug Type, 2017-2031
6.3.1. PARP Inhibitors
6.3.2. Alkylating Agents
6.3.3. Others
  6.4. Market Attractiveness Analysis, by Drug Type
7. Global DNA Repair Drugs Market Analysis and Forecast, by Dosage Form
  7.1. Introduction & Definition
  7.2. Key Findings/Developments
  7.3. Market Value Forecast, by Dosage Form, 2017-2031
7.3.1. Breast Cancer
7.3.2. Ovarian Cancer
7.3.3. Lung Cancer
7.3.4. Head and Neck Cancer
7.3.5. Others
  7.4. Market Attractiveness Analysis, by Dosage Form
8. Global DNA Repair Drugs Market Analysis and Forecast, by Dosage Form
  8.1. Introduction & Definition
  8.2. Key Findings/Developments
  8.3. Market Value Forecast, by Dosage Form, 2017-2031
8.3.1. Tablets
8.3.2. Capsules
8.3.3. Injectables
  8.4. Market Attractiveness Analysis, by Dosage Form
9. Global DNA Repair Drugs Market Analysis and Forecast, by Distribution Channel
  9.1. Introduction & Definition
  9.2. Key Findings/Developments
  9.3. Market Value Forecast, by Distribution Channel, 2017-2031
9.3.1. Retail Pharmacies
9.3.2. Hospital Pharmacies
9.3.3. Online Pharmacies
  9.4. Market Attractiveness Analysis, by Distribution Channel
10. Global DNA Repair Drugs Market Analysis and Forecast, by Region
  10.1. Key Findings
  10.2. Market Value Forecast, by Region, 2017-2031
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
  10.3. Market Attractiveness By Country/Region
11. North America DNA Repair Drugs Market Analysis and Forecast
  11.1. Introduction
11.1.1. Key Findings
  11.2. Market Value Forecast, by Drug Type, 2017-2031
11.2.1. PARP Inhibitors
11.2.2. Alkylating Agents
11.2.3. Others
  11.3. Market Value Forecast, by Dosage Form, 2017-2031
11.3.1. Breast Cancer
11.3.2. Ovarian Cancer
11.3.3. Lung Cancer
11.3.4. Head and Neck Cancer
11.3.5. Others
  11.4. Market Value Forecast, by Dosage Form, 2017-2031
11.4.1. Tablets
11.4.2. Capsules
11.4.3. Injectables
  11.5. Market Value Forecast, by Distribution Channel, 2017-2031
11.5.1. Retail Pharmacies
11.5.2. Hospital Pharmacies
11.5.3. Online Pharmacies
  11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
11.6.1. U.S.
11.6.2. Canada
  11.7. Market Attractiveness Analysis
11.7.1. By Drug Type
11.7.2. By Dosage Form
11.7.3. By Dosage Form
11.7.4. By Distribution Channel
11.7.5. By Country/Sub-region
12. Europe DNA Repair Drugs Market Analysis and Forecast
  12.1. Introduction
12.1.1. Key Findings
  12.2. Market Value Forecast, by Drug Type, 2017-2031
12.2.1. PARP Inhibitors
12.2.2. Alkylating Agents
12.2.3. Others
  12.3. Market Value Forecast, by Dosage Form, 2017-2031
12.3.1. Breast Cancer
12.3.2. Ovarian Cancer
12.3.3. Lung Cancer
12.3.4. Head and Neck Cancer
12.3.5. Others
  12.4. Market Value Forecast, by Dosage Form, 2017-2031
12.4.1. Tablets
12.4.2. Capsules
12.4.3. Injectables
  12.5. Market Value Forecast, by Distribution Channel, 2017-2031
12.5.1. Retail Pharmacies
12.5.2. Hospital Pharmacies
12.5.3. Online Pharmacies
  12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
  12.7. Market Attractiveness Analysis
12.7.1. By Drug Type
12.7.2. By Dosage Form
12.7.3. By Dosage Form
12.7.4. By Distribution Channel
12.7.5. By Country/Sub-region
13. Asia Pacific DNA Repair Drugs Market Analysis and Forecast
  13.1. Introduction
13.1.1. Key Findings
  13.2. Market Value Forecast, by Drug Type, 2017-2031
13.2.1. PARP Inhibitors
13.2.2. Alkylating Agents
13.2.3. Others
  13.3. Market Value Forecast, by Dosage Form, 2017-2031
13.3.1. Breast Cancer
13.3.2. Ovarian Cancer
13.3.3. Lung Cancer
13.3.4. Head and Neck Cancer
13.3.5. Others
  13.4. Market Value Forecast, by Dosage Form, 2017-2031
13.4.1. Tablets
13.4.2. Capsules
13.4.3. Injectables
  13.5. Market Value Forecast, by Distribution Channel, 2017-2031
13.5.1. Retail Pharmacies
13.5.2. Hospital Pharmacies
13.5.3. Online Pharmacies
  13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
  13.7. Market Attractiveness Analysis
13.7.1. By Drug Type
13.7.2. By Dosage Form
13.7.3. By Dosage Form
13.7.4. By Distribution Channel
13.7.5. By Country/Sub-region
14. Latin America DNA Repair Drugs Market Analysis and Forecast
  14.1. Introduction
14.1.1. Key Findings
  14.2. Market Value Forecast, by Drug Type, 2017-2031
14.2.1. PARP Inhibitors
14.2.2. Alkylating Agents
14.2.3. Others
  14.3. Market Value Forecast, by Dosage Form, 2017-2031
14.3.1. Breast Cancer
14.3.2. Ovarian Cancer
14.3.3. Lung Cancer
14.3.4. Head and Neck Cancer
14.3.5. Others
  14.4. Market Value Forecast, by Dosage Form, 2017-2031
14.4.1. Tablets
14.4.2. Capsules
14.4.3. Injectables
  14.5. Market Value Forecast, by Distribution Channel, 2017-2031
14.5.1. Retail Pharmacies
14.5.2. Hospital Pharmacies
14.5.3. Online Pharmacies
  14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
  14.7. Market Attractiveness Analysis
14.7.1. By Drug Type
14.7.2. By Dosage Form
14.7.3. By Dosage Form
14.7.4. By Distribution Channel
14.7.5. By Country/Sub-region
15. Middle East & Africa DNA Repair Drugs Market Analysis and Forecast
  15.1. Introduction
15.1.1. Key Findings
  15.2. Market Value Forecast, by Drug Type, 2017-2031
15.2.1. PARP Inhibitors
15.2.2. Alkylating Agents
15.2.3. Others
  15.3. Market Value Forecast, by Dosage Form, 2017-2031
15.3.1. Breast Cancer
15.3.2. Ovarian Cancer
15.3.3. Lung Cancer
15.3.4. Head and Neck Cancer
15.3.5. Others
  15.4. Market Value Forecast, by Dosage Form, 2017-2031
15.4.1. Tablets
15.4.2. Capsules
15.4.3. Injectables
  15.5. Market Value Forecast, by Distribution Channel, 2017-2031
15.5.1. Retail Pharmacies
15.5.2. Hospital Pharmacies
15.5.3. Online Pharmacies
  15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
  15.7. Market Attractiveness Analysis
15.7.1. By Drug Type
15.7.2. By Dosage Form
15.7.3. By Application
15.7.4. By Distribution Channel
15.7.5. By Country/Sub-region
16. Competition Landscape
  16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  16.2. Market Share Analysis, by Company (2021)
  16.3. Company Profiles
16.3.1. AstraZeneca plc
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Clovis Oncology
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. GlaxoSmithKline plc
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Pfizer Inc.
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Merck & Co. Inc.
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Novartis AG
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Johnson & Johnson
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Bristol Myers Squibb Company
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Onxeo
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings